Allergy, Immunology & Rheumatology

An article details an arthritis drug called Enbrel that seems to significantly cut the risk of developing Alzheimer’s disease, and the decision by the drug’s manufacturer to not develop the drug for this condition because the patent on it will soon expire and the company will not profit from pursuing it further. It reports that in 2016, Richard C. Chou, MD, PhD, associate professor of medicine in the Division of Allergy, Immunology and Rheumatology, and colleagues published an analysis that showed that of 300-odd people with rheumatoid arthritis, those on Enbrel were about a third as likely to get Alzheimer’s as those on other treatments.
A story about climate change and the impact it is having on seasonal allergies includes an interview with Stanley A. Schwartz, MD, PhD, UB Distinguished Professor of medicine and pediatrics and chief of the Division of Allergy, Immunology and Rheumatology. “Plants are changing. They’re changing their blooming habits, we're seeing longer periods of time when we have green plants growing, even in a northern climate like this,” he said.
A story about the various illnesses that are going around now that the weather is becoming more spring-like interviews Stanley A. Schwartz, MD, PhD, UB Distinguished Professor of medicine and pediatrics. “The spring’s a funny time,” said Schwartz, chief of the Department of Medicine’s Division of Allergy, Immunology and Rheumatology. “In the springtime there are a whole bunch of different viruses that become very prevalent. Most of them are harmless ... harmless in the sense that they're not going to kill you, but you may feel like you're going to die.”
Stanley A. Schwartz, MD, PhD, UB Distinguished Professor of medicine and pediatrics and division chief of allergy, immunology and rheumatology, is interviewed on the role that pollution plays in the high rates of asthma among minority residents in Buffalo.  Schwartz said that as Rust Belt cities like Detroit, Cleveland and Buffalo lost manufacturing jobs, some neighborhoods crumbled. “So, air pollution, lack of good sanitary conditions in inner cities all contribute to why you many see a disparity. And who lives in the inner city? Usually it’s underserved minority individuals, so that goes hand in glove.”
Sean P. Brady, MD, clinical assistant professor of medicine in the Division of Allergy, Immunology & Rheumatology, was interviewed about spring allergies. He said that this time of year, “Patients with allergies to both types of pollen (tree and grass pollen) are really getting hit,” adding that asthmatic patients are even more vulnerable.
The New York Center for Nanomedicine Research, co-founded by Stanley A. Schwartz, MD, PhD, SUNY Distinguished Professor of medicine, ended its first six months with a dozen staffers and more than $1 million in revenue. The company applies nanotechnology to clinical applications and its roots go back several years, when a $1.2 million state grant helped Schwartz co-found a center to train physician-researchers in nanomedicine. 
Stanley A. Schwartz, MD, PhD, distinguished professor of medicine, comments on a plastic device that transfers vibrations to the airways in the lung. The device has helped emphysema patients, and it is now being tested in asthmatics. “When the lungs pick up this vibration, they amplify the vibration, and that’s what helps mobilize the sputum,” says Schwartz.
Kaleida Health received a grant that will be used to develop a Center for Nanomedicine in collaboration with the University at Buffalo. The group — led by Stanley A. Schwartz, MD, PhD, of the Department of Medicine, and Adnan Siddiqui MD, PhD, of neurosurgery — will develop a transdisciplinary physician-scientist fellowship training program in global vascular pathobiology, among other things.
Allergy, immunology and rheumatology expert Stanley A. Schwartz MD, PhD, discusses Buffalo’s ranking as the 15th worst city for allergy sufferers.
Julian L. Ambrus Jr., associate professor of medicine, discusses three new antibodies that can be tested for the presence of Sjogren’s syndrome, an autoimmune disorder affecting 4 million Americans.
Patients would benefit from a much-needed early diagnosis, says senior author on the study, Julian L. Ambrus Jr., MD, professor of medicine.
Research conducted by Julian L. Ambrus Jr., MD, professor of medicine, and Long Shen, PhD, will help people with the autoimmune disorder Sjogren’s Syndrome receive treatment for painful symptoms sooner.